Palmetto
Palmetto Finalizes Medicare Coverage for MRD Cancer Testing
To receive coverage, the patient must have a personal history of cancer where the type and staging are within the intended use of the test.
Genomic Testing Cooperative's Hematologic Neoplasms, Solid Tumor Tests Receive NY State Approval, Medicare Coverage
The next-generation sequencing-based tests can be performed on small samples, including needle aspiration samples, and use artificial intelligence software.
Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD
The draft LCD would cover the Signatera minimal residual disease test for several solid tumor types and indications, including immunotherapy response monitoring.
Palmetto Issues Final LCD for Decipher Biosciences Prostate Cancer Test
The LCD will provide coverage for the Decipher Prostate Biopsy genomic test for men with both favorable and unfavorable intermediate-risk prostate cancer.Â
CMS to Revisit National Coverage Determination on NGS Tumor Testing
CMS had received significant stakeholder feedback that germline NGS testing is not the same as somatic testing, and that the NCD as written would negatively impact patients.